Targeted Therapies Driving the European Head and Neck Cancer Therapeutics Markets

26-Sep-2007

Despite improvements in surgical techniques and the development of novel chemoradiotherapy strategies, survival rates in patients with head and neck cancer has remained relatively unchanged over the last 30 years. While this could be due to the absence of any significant advancements in treatment techniques, newer targeted therapies now hold out great promise for the future. Pharmaceutical companies that succeed in increasing efficacy, lowering toxicity and improving survival rates can expect to gain position in the emerging European head and neck cancer therapeutics markets.

New analysis from Frost & Sullivan, European Head and Neck Cancer Therapeutics Markets, reveals that revenues in this market totalled $9.9 million in 2006, and are likely to reach $171.5 million in 2013.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances